RECOVERY & TISSUE REPAIR
Recovery & Tissue Repair research peptides
A calm, cited reference desk on three peptides studied for tendon load, gut mucosa, wound healing and the biology of recovery under hard training.
TB-500
A synthetic fragment of thymosin beta-4, studied for its role in cell migration, angiogenesis and reduced scarring — mostly in animal models of injury.
Read more ›KPV
The lead compound on this desk. An anti-inflammatory tripeptide derived from alpha-MSH, studied almost entirely in gut-mucosa and colitis models.
Read more ›KLOW
A four-peptide research blend — KPV, GHK-Cu, BPC-157 and TB-500 — combining cytokine, matrix, vascular and cytoskeletal mechanisms in one vial.
Read more ›The short version
This site is a reading desk for three research peptides that keep coming up in conversations about recovery from hard physical training: TB-500, KPV, and the blend KLOW. A peptide is a short chain of amino acids, the same building blocks that make up larger proteins, only much smaller. Each of these three is studied in laboratories for how it might influence the body's own repair machinery — cell movement, blood-vessel growth, and the signals that turn inflammation up or down.
Hard training puts real, repeated stress on tendons, ligaments and the gut lining, and the literature on these compounds is mostly about that kind of stress: how tissue heals, how inflammation resolves, and how a body under load rebuilds. None of this page recommends using anything, and none of it lists a dose meant for a person. It reports what has been studied, in which species, and how far that evidence actually reaches.
Recovery under hard training
Consistent hard training creates a predictable pattern of small injuries: micro-tears in tendon and muscle tissue, low-grade inflammation, and — for endurance and strength athletes alike — gut lining that takes a beating from blood flow diversion and mechanical jostling. The three compounds on this desk sit at different points along that repair pathway.
TB-500 is studied for the actin-binding biology that underlies cell migration and new blood-vessel formation — processes relevant to how injured tissue rebuilds itself, though almost all of the strongest data come from the full-length parent protein rather than the short fragment sold under this name. KPV, the lead compound here, has an almost entirely different research base: it is studied for calming inflammatory signaling at the gut lining, with essentially no data outside cell cultures and mouse colitis models. KLOW combines both of those mechanisms with two more — copper-dependent matrix synthesis and a nitric-oxide-linked vascular pathway — in a single co-formulated vial, though the blend itself has never been tested as a unit.
What are research peptides?
"Research peptide" is the term suppliers use for short amino-acid chains sold strictly for laboratory use, not for human or animal consumption. Some, like TB-500, are fragments of a naturally occurring human protein (thymosin beta-4). Others, like KPV, are themselves a small piece of a larger hormone (alpha-melanocyte-stimulating hormone) that keeps some of the parent molecule's activity while dropping other parts of it. KLOW is not a single molecule at all — it is four separate peptides co-dissolved in one vial at fixed proportions.
None of the three compounds covered here is an FDA-approved medicine. The available evidence ranges from cell-culture and rodent studies (KPV, most of KLOW's rationale) to a mix of animal work and a handful of small human safety studies (TB-500, by way of the full-length parent protein). Where this site reports a number from a study — a percentage, a dose used in an experiment, a species — it always names the study and the species, and it never turns that number into a recommendation.
How these three compounds relate
TB-500 and KPV are the two single-molecule compounds most often discussed together in hard-training recovery contexts, precisely because their proposed mechanisms are complementary rather than overlapping: TB-500's actin-binding, pro-migration biology on one side, KPV's cytokine-suppressing, gut-selective biology on the other. KLOW exists as an attempt to package that complementarity, adding GHK-Cu and BPC-157 to reach four non-overlapping nodes of the same general repair network — cytokine suppression, matrix remodeling, vascular supply and cytoskeletal mobility.
What unites all three pages on this desk is a plain fact worth stating up front: none of the three peptides in their commercial form has been tested against placebo in a controlled human trial. TB-500's efficacy data lean heavily on full-length thymosin beta-4 rather than the fragment sold commercially; KPV's entire efficacy literature is preclinical; and KLOW's four-peptide combination has never been tested as a unit at all. Compare the three side by side for a direct look at where the evidence for each one currently stands, or start with the FAQ for direct answers to the questions readers ask most.